Arovella Therapeutics Limited (ASX:ALA) Share Market Overview and Healthcare Sector Profile

Anjali Anand

11 August 2026 11:18 PM AEST

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Arovella Therapeutics Limited (ASX:ALA) shares traded at $0.062 during the latest session.
The company recorded a daily share price movement of +3.333%, with trading Volume of 929,636 shares.
Arovella Therapeutics Limited recorded a Market Capitalisation of $72.53M.
The stock traded within a daily range of $0.060 to $0.062.
ALA shares recorded a 52-week trading range between $0.058 and $0.125.

Arovella Therapeutics Limited (ASX:ALA) Market Overview

Arovella Therapeutics Limited (ASX:ALA) is an Australian Securities Exchange-listed company operating within the pharmaceuticals, biotechnology and life sciences industry group. The company’s shares were trading at $0.062, with a daily movement of +3.333%.

This article provides an educational overview of Arovella Therapeutics’ available market information, including share price activity, trading volume, market capitalisation and key share statistics.

Share Price Movement and Trading Activity

Arovella Therapeutics Limited recorded a share price of $0.062 during the latest trading session, compared with the previous close of $0.060. The stock recorded a daily movement of +$0.002, representing a percentage change of +3.333%.

During the session, ALA shares traded within a range of $0.060 to $0.062. The company recorded trading volume of 929,636 shares, while the average trading volume was 926,286 shares.

Trading volume provides an indication of the number of shares exchanged during a trading session. It is commonly reviewed alongside share price movements to understand market activity for listed securities.

Market Capitalisation and Share Information

Arovella Therapeutics Limited recorded a market capitalisation of $72.53M. Market capitalisation represents the total Market Value of a company’s listed shares based on its current share price and shares outstanding.

The company has 1,208,851,853 shares on issue, with ordinary fully paid shares listed on the Australian Securities Exchange.

The company’s International Securities Identification Number (ISIN) is AU0000182784.

Historical Trading Range

Arovella Therapeutics Limited shares recorded a 52-week trading range between $0.058 and $0.125.

The 52-week range provides a reference point for understanding the highest and lowest trading levels reached by the stock over the previous year. Historical price movements can provide context on how the share price has changed over a particular period.

The company’s trading activity reflects movements in the listed market and may be influenced by broader market conditions, sector trends and company-related developments.

Pharmaceuticals, Biotechnology and Life Sciences Sector

Arovella Therapeutics Limited is classified within the pharmaceuticals, biotechnology and life sciences industry group. This sector includes companies involved in developing healthcare-related products, technologies and solutions.

Companies operating within this sector can experience share price movements influenced by factors such as research developments, regulatory processes, industry conditions and market participation.

For listed healthcare companies, investors and market observers often review share price performance, trading activity, company announcements and financial disclosures to understand developments over time.

Listing History and Market Information

Arovella Therapeutics Limited was listed on the Australian Securities Exchange on 24 January 2002.

The company’s ordinary fully paid shares trade under the ticker code ASX:ALA. The stock’s market information includes daily price movement, trading volume, market capitalisation and historical trading range, which provide a snapshot of its position in the listed market.

The available share statistics allow Market Participants to track changes in the company’s trading activity and share performance.

Understanding ASX Share Data

Share price information represents market activity during a specific period and can change based on buying and selling activity in the market.

Metrics such as market capitalisation, trading volume, daily range and historical trading range are commonly used to review listed companies. These indicators provide market-based information but do not represent a complete assessment of a company’s operations or future performance.

Additional company disclosures, financial reports and official announcements provide further information about Business activities and developments.

Conclusion

Arovella Therapeutics Limited (ASX:ALA) recorded a share price of $0.062, with a daily increase of 3.333% and trading volume of 929,636 shares. The company had a market capitalisation of $72.53M and operates within the pharmaceuticals, biotechnology and life sciences industry group. With a 52-week trading range of $0.058 to $0.125, ALA’s market activity reflects the ongoing movement of its listed shares. This overview provides an educational summary of available market information and does not include financial advice or Investment recommendations.

FAQs

Q: What is the ASX ticker code for Arovella Therapeutics Limited?

A:Arovella Therapeutics Limited is listed on the Australian Securities Exchange under the ticker code ASX:ALA.

Q: What was Arovella Therapeutics Limited’s latest share price?

A:Arovella Therapeutics Limited shares were trading at $0.062.

Q: What was the daily share price movement for ASX:ALA?

A:The company recorded a daily share price increase of +3.333%.

Q: What is Arovella Therapeutics Limited’s market capitalisation?

A:Arovella Therapeutics Limited recorded a market capitalisation of $72.53M.

Q: Which industry group does Arovella Therapeutics Limited belong to?

A:Arovella Therapeutics Limited belongs to the pharmaceuticals, biotechnology and life sciences industry group.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.